Paul R Sanberg

This inventor holds 59 USPTO granted patents and 9 published patent applications and 1 EPO patent, primarily in Neurodegenerative Disorders (CPC class 4244). Top assignees: University of South Florida, Brown University, Saneron Ccel Therapeutics, Inc.. Active years: 1996-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paul R Sanberg. Retrieved from https://idiyas.com/inventor/paul-r-sanberg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 59 (Patent Applications = 9)

% Patents Active = 69.5

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 3.2

ph-index = 15

Forward Citations = 1,574(Granted Patents)

Forward Citations (Not Self Cited) = 1,533(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Greenwich, RI (US) (1996 - 2001)
Tampa, FL (US) (2010)
Spring Hill, FL (US) (1997 - 2023)

Company Filing History:

46 out of 1,990

University of South Florida

Saneron Ccel Therapeutics, Inc.

patents

4. 2 out of 3

Natura Therapeutics, Inc.

patents

5. 2 out of 958

The United States Government as Represented by the Department of Veterans Affairs

patents

6. 1 out of 16

Cryo-Cell International, Inc.

patents

7. 1 out of 1

Cryopraxis Criobiologia Ltda.

patent

8. 1 out of 51

Medical College of Georgia

Stemco Biomedical, Inc.

Thomas Jefferson University

patents

13. 1 out of 3

Universidade Federal De São Paulo - Unifesp

patents

where one patent can have more than one assignee

Years Active: 1996-2026

Loading Chart...

Areas of Expertise:

Neurodegenerative Disorders

Stem Cell Therapy

Cognitive Performance

Human Umbilical Cord Blood

Amyloid Precursor Protein

Blood Brain Barrier

Ischemic Tissue

Nicotinic Receptor Antagonists

Immunosuppressive Protein

Stroke Treatment

Sertoli Cells

Therapeutic Agents

59 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12605409 - Plasma derived from human umbilical cord blood for the treatment of neurodegenerative disorders (2026-04-21),

2. 12144832 - Plasma derived from human umbilical cord blood for the treatment of neurodegenerative disorders (2024-11-19),

3. 11766429 - Nicotinic receptor antagonists and pioglitazone as therapeutic agents for Covid-19 (2023-09-26),

4. 11628190 - Plasma derived from human umbilical cord blood for the treatment of neurodegenerative disorders (2023-04-18),

5. 11007230 - Plasma derived from human umbilical cord blood for the treatment of neurodegenerative disorders (2021-05-18),

6. 10765706 - Method of stem cell delivery into the brain during chronic disease using blood brain barrier permeabilizers (2020-09-08),

7. 10335434 - Ischemic tissue cell therapy (2019-07-02),

8. 10188613 - Exo-S-mecamylamine formulation and use in treatment (2019-01-29),

9. 10130683 - Combination therapy of stem cell mobilizing agents and stem cell transplantation (2018-11-20),

10. 10039785 - HUCBC treatment of amyloid-associated disease (2018-08-07),

11. 9926354 - Amyloid precursor protein (APP) based Ã#-secretase inhibitor peptides, and methods of use (2018-03-27),

12. 9827285 - Compositions and methods of improving cognitive performance (2017-11-28),

13. 9795637 - Human cord blood as a source of neural tissue repair of the brain and spinal cord (2017-10-24),

14. D795156 - Wiper blade ornament (2017-08-22),

15. D793944 - Wiper blade ornament (2017-08-08),

Dr. Paul Sanberg is the President and founder of the National Academy of Inventors and a Distinguished University Professor and Executive Director of the Center of Excellence for Aging & Brain Repair at the University of South Florida. His pioneering work has been crucial in advancing new pharmaceutical and cellular therapeutics to clinical trials and commercialization for various neurological conditions, including Tourette syndrome, stroke, ALS, Alzheimer's, Huntington's, and Parkinson's diseases. Dr. Sanberg brings extensive experience in the biotech and pharmaceutical industries, underscored by his role as an inventor on 57 U.S. and 113 foreign patents.

Dr. Sanberg's influence extends beyond his research. He serves as the editor-in-chief of both Technology and Innovation – Journal of the National Academy of Inventors and Cell Transplantation, two prestigious publications in the field. His contributions have been recognized with numerous awards, such as the AIMBE Fellow Advocate Award, Bryden Alumni Award for Outstanding Achievement (York University), Australian National University Alumni Award, University of British Columbia Entrepreneurship Alumni Award, Fulbright Specialist designation, John P. McGovern Science & Society Award (Sigma Xi), NAI Founders Award, Florida Academy of Sciences Gold Medal, and the Pioneer Award from the Florida Inventors Hall of Fame, among others.